<DOC>
	<DOCNO>NCT02065596</DOCNO>
	<brief_summary>This phase I/II study patient sickle cell disease . It aim find people sickle cell disease cure change immune system blood stem cell transplant . Doctors give patient new drug ( fludarabine ) see drug change patient immune system reduce patient 's cell ( host ) reject donor cell ( graft ) patient get Hematopoietic ( blood ) stem cell transplant .</brief_summary>
	<brief_title>Hematopoietic Stem Cell Transplant Sickle Cell Disease</brief_title>
	<detailed_description>Primary Objective 1 . To evaluate safety feasibility hematopoietic stem cell transplant ( HSCT ) treatment fludarabine adult patient Sickle Cell Disease ( SCD ) . Secondary Objective ( ) , HSCT SCD 1 . To evaluate rate disease-free overall survival MSD alternate graft donor ( MUD , haploidentical , cord blood-derived ) recipients 2 . To evaluate fertility match sibling alternate-donor graft recipient 3 . To evaluate GVHD rate MSD Alternate Graft Donor recipient SCD . 4 . To evaluate cerebral , pulmonary , renal , generalize vasculopathy HSCT SCD . 5 . To evaluate hematopoiesis erythropoiesis HSCT SCD . 6 . Modulation SCD Phenotype Allogeneic Transplantation . Rigorous clinical follow-up perform , per routine care , evaluate consequence SCD modify allogeneic transplantation short-term ( 4-12 week ) , medium-term ( 12-24 week ) long-term ( &gt; 24 week ) . Short-term change would include disappearance stress hematopoiesis erythropoiesis ; medium- long-term change would include effect pain , fertility ( TSH , LH ) , cognition ( routine cognitive assessment ) , end-organ damage ( include urine albumin-to-creatinine ratio tricuspid regurgitant jet velocity , indicate ) . Procedures : The study start least 10 25 patient . They give low start dose fludarabine . This do make sure safe . Researchers watch patient call dose-limiting toxicity ( DLT ) period . Their safety monitor Safety Monitoring Committee , make people run research study . The study take new patient DLT period do . If least 3 10 patient enrolled benefit , maximum tolerate dose ( MTD ) consider exceed . After DLT period complete , patient receive stem cell transplant genetically match donor . Patients continue monitored year transplant . To prepare transplant patient undergo follow treatment : - exchange transfusion - stem cell graft infusion either : - perfectly match sibling donor ( call MSD ) , - perfectly match unrelated donor ( call MUD ) , - half-matched related donor ( call Haploidentical ) , - cord blood donor - rabbit antithymocyte globulin ( ATG ) - cytoxan ( type chemotherapy ) - Fludarabine ( get medicine week transplant , part routine chemotherapy treatment ) . This main drug study research - total body irradiation ( also call TBI ) - tacrolimus , mycophenolate ( MMF ) and/or methotrexate ( MTX ) . These drug weaken immune system . They give low chance get GVHD reject donor cell . Patients study approximately 14 month .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients must one follow inherit hemoglobin gene disorder : a. Hemoglobin SS b. Hemoglobin SC c. Hemoglobin SBetazeroThalassemia d. Hemoglobin SBetaplus Thalassemia episode multiorgan failure within 5 year eligibility Low Risk ( Red Light . Stop consider therapy closely ) : Must match sibling donor graft , fail conventional therapy determine PI , evidence morbid disease ( one follow ) : . 2 painful episode/year ( require Emergency Department inpatient care ) x 2 year b . 1 diagnosis Acute Chest Syndrome within 5 year , c. 2year mortality 510 % d. Baseline LDH &gt; 600 IU e. History sepsis , without WBC &gt; 13.5 , f. On chronic transfusion Moderate Risk ( Yellow Light . Reasonable proceed , caution ) : May alternate donor graft ( haploidentical match unrelated donor ) , MSD available . Must history highlevel vasculopathy , define least one criterion : a. Urine Albumin Creatinine Ratio &gt; 300mg/g eGFR 5090 ml/min x 2 evaluation within 3 month b . History overt clinical stroke , progressive cerebral vasculopathy radiographically c. 2 diagnosis Acute Chest Syndrome within 5 year , d. Excessively morbid disease manifest VOCs rate 2 per year x 2years uncontolled retinal disease attribute SCD . These patient consider moderaterisk alternate donor transplant . The palliative nature transplant explicit consent . e. 2year mortality &gt; 1015 % f. Baseline WBC &gt; 13.5 chronic transfusion baseline LDH &gt; 600 age &gt; 35 year old , g. Baseline TRV ≥3 m/s , h. Chronic transfusion therapy age &gt; 35 year old male gender , i. Baseline LDH &gt; 600 age &gt; 35 year old history sepsis j . History sepsis age &gt; 35 year old male gender . k. History multiorgan failure High Risk ( Green light , proceed possible ) : All donor type eligible . Must high risk disease &gt; 15 % risk 2year mortality define least one criterion . a. Baseline TRV ≥3 m/s baseline WBC &gt; 13.5 chronic transfusion history sepsis age &gt; 35 year old , b. Baseline WBC &gt; 13.5 chronic transfusion baseline LDH &gt; 600 age &gt; 35 year old c. Age &gt; 35 year old chronic transfusion Available suitable donor . 6/6 HLAmatched sibling donor ( HLA A , B , DRB1 ) , bone marrow b . 8/8 HLAmatched unrelated donor ( HLA A , B , C , DRB1 ) , bone marrow c. 4/8 , 5/8 , 6/8 , 7/8 Haploidentical donor , bone marrow d. Cord Blood , availability 2 unit 6/8 , 7/8 , 8/8 match ( HLAA , B , &amp; C ) . Overall : class I A , B Class II DRBII match . Class I A , B low intermediate resolution ( serology and/or molecular ) class II must molecular high resolution . Patients must adequate hematologic , hepatic , renal function define : Direct bilirubin within 2.5 X normal institutional limit ALT ( SGPT ) &lt; 2.5 X institutional upper limit normal Creatinine clearance &gt; 21 mL/min/1.73 m2 subject creatinine clearance value 50 mL/min/1.73 m2 , principal investigator may use discretion appropriate fludarabine dose adjustment note . Contraception/Child Bearing The effect Fludarabine , cytoxan , ATG , tacrolimus/sirolimus MTX cumulatively know deleterious health develop human fetus . For reason , teratogenic potential , woman childbearing potential men must agree use adequate contraception ( double barrier method birth control abstinence ) duration study participation 12 month complete treatment . Performance Status : Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤ 2 Subjects must ability understand willingness sign write informed consent document . Red cell alloimmunization degree precludes extend transfusion Patients uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Subjects must evidence impair liver function due iron overload , +/ hepatitis . Patients evaluate liver consult ferritin &gt; 1500 , history hepatitis , ALTis ≥3 X Upper limit normal ( ULN ) . Recommended evaluation could include liver biopsy evidence significant hepatic iron deposition fibrosis/cirrhosis T2* MRI liver . eGFR &lt; 21 ml/min ≥2.0 literperminute pm home oxygen requirement An estimate Left Ventricular Ejection Fraction ≤40 % ( echo MUGA ) Hepatic cirrhosis ( Biopsy Proven ) HIV positive , ineligible increase risk lethal infection treat marrow suppressive therapy . Appropriate study undertake patient receive combination antiretroviral therapy indicate Red cell alloimmunization degree precludes extend transfusion Patients uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant breastfeed woman exclude study immunomodulatory treatment , preparative regimen , antiGVH therapy contain agent potential teratogenic abortifacient effect . Further , treatment , indicate , chronic condition , delayed pregnancy successfully conclude . Because unknown , potential risk adverse event nurse infant secondary treatment mother , breastfeed discontinue mother treated agent . These potential risk may also apply agent use study . Evidence uncontrolled bacterial , viral , fungal infection ( currently take medication progression clinical symptom ) within 1 month prior start condition regimen . Patients fever suspect minor infection await resolution symptom start condition regimen . Prior allogeneic marrow stem cell transplantation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Sickle Cell Disease</keyword>
	<keyword>Sickle Cell Anemia</keyword>
	<keyword>GvHD</keyword>
	<keyword>fludarabine</keyword>
</DOC>